OBJECTIVE: To determine whether an interim
18F-fluoride positron-emission tomography/computed tomography (PET/CT) study performed after the third cycle of radium-223 dichloride (
223RaCl
2) therapy is able to identify patients that will not respond to treatment.
MATERIALS AND METHODS: We retrospectively reviewed 34 histologically confirmed cases of hormone-refractory prostate cancer with bone metastasis in patients submitted to
223RaCl
2 therapy. All of the patients underwent baseline and interim
18F-fluoride PET/CT studies. The interim study was performed immediately prior to the fourth cycle of
223RaCl
2. The skeletal tumor burden—expressed as the total lesion fluoride uptake above a maximum standardized uptake value of 10 (TLF
10)—was calculated for the baseline and the interim studies. The percent change in TLF
10 between the baseline and interim studies (%TFL
10) was calculated as follows: %TFL
10 = interim TLF
10 − baseline TLF
10 / baseline TLF
10. End points were overall survival, progression-free survival, and skeletal-related events.
RESULTS: The mean age of the patients was 72.4 ± 10.2 years (range, 43.3–88.8 years). The %TLF
10 was not able to predict overall survival (
p = 0.6320; hazard ratio [HR] = 0.753; 95% confidence interval [CI]: 0.236–2.401), progression-free survival (
p = 0.5908; HR = 1.248; 95% CI: 0.557–2.797) nor time to a bone event (
p = 0.5114; HR = 1.588; 95% CI: 0.399–6.312).
CONCLUSION: The skeletal tumor burden on an interim
18F-fluoride PET/CT, performed after three cycles of
223RaCl
2, is not able to predict overall survival, progression-free survival, or time to bone event, and should not be performed to monitor response at this time.
Keywords: Sodium fluoride; Positron-emission tomography/methods; Tomography, X-ray computed/methods; Prostatic neoplasms; Radium-223; Bone neoplasms/diagnostic imaging; Tumor burden.